Merit Medical Systems Inc (MMSI)
Merit Medical Systems Inc is a global developer and manufacturer of innovative medical devices used in minimally invasive procedures, primarily in cardiology, radiology, urology, and critical care. Founded in 1987, the company focuses on creating products that improve patient outcomes and healthcare provider efficiency, offering a diverse portfolio of disposables, accessories, and innovative technologies for various diagnostic and therapeutic applications.
Company News
Merit Medical Systems has signed an asset purchase agreement with PENTAX Medical to acquire the C2 CryoBalloon device for $22 million, expanding its endoscopy portfolio in the gastroenterology market with technology to treat Barrett's esophagus and other gastrointestinal disorders.
Merit Medicine has integrated Willis Towers Watson's HealthMAPS® manuals into its Merit Predict predictive analytics solution, enabling more precise group health risk assessment by combining actuarial expertise with advanced predictive modeling.
Merit Medical Systems reported strong Q2 2025 financial results, with revenue of $382.5 million (up 13.2%), beating analyst estimates. The company showed robust growth in cardiovascular and endoscopy device segments and raised its full-year guidance.
Merit Medical Systems, Inc. reported better-than-expected Q2 2024 results, with adjusted EPS up 16.8% year-over-year and revenues increasing 5.6%. The company saw growth across its Cardiovascular and Endoscopy segments, and raised its full-year 2024 guidance.
Oppenheimer raised its price target for AngioDynamics stock to $13 from $12, citing the company's strong fourth-quarter sales, particularly in its higher-margin and growth segments. The firm also noted AngioDynamics' efforts to expand EBITDA and reach profitability by fiscal year 2027.
